Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland

Fig. 1

Cohort construction flowchart. From 19.03.2013 to 01.07.2013, 199 applications were submitted to the drug programme. The analysis included a total of 95 patients - only those who initiated therapy with OMB. Sixty-nine patients who had previously received OMB and continued treatment were excluded, as were patients who, for various reasons, were not eligible for this therapy (35 patients). The most common cause of non-eligibility was prior treatment with OMB for a period longer than 36 months (22 patients), as it was initially assumed that the duration of treatment should not exceed 3 years. This was subsequently changed, and now the physician, based on clinical data, decides on the cessation of treatment. The other cause was an inability to determine the dose of the drug by serum total IgE level (IU/mL) measured before the start of treatment and by body weight (kg). Five patients were outside the dosing table, and 2 patients did not meet inclusion criteria; one of them was not allergic, and the other had a tIgE greater than 1500 (IU/mL). Five patients resigned prior to the first dose. Of the 95 patients who started OMB treatment, ten discontinued this therapy before Week 52 (second monitoring point), three of them due to treatment failure observed in Week 16 (first monitoring visit). For the other patients, the treatment was discontinued for reasons such as pregnancy, withdrawal of consent for treatment, and adverse reactions. A group of 85 patients continued the treatment until Week 52, at which time they were evaluated for efficacy and safety. Therapy was then continued in 83 of these patients. Two patients were excluded at this point due to lack of efficacy (one patient) and side effects in the form of generalized erythematous oedema lesions (one patient)

Back to article page